Genmab
Trial to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of GEN1286 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Genmab
- Target Recruit Count
- 214
- Registration Number
- NCT06685068
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 702
- Registration Number
- NCT06635824
- Locations
- 🇺🇸
Ocala Oncology Center P.L., Ocala, Florida, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇯🇵Miyagi Cancer Center, Natori-shi, Japan
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 530
- Registration Number
- NCT06619236
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Genmab
- Target Recruit Count
- 45
- Registration Number
- NCT06573294
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇦🇺
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland, Australia
🇧🇪Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale, Belgium
🇧🇪AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen, Belgium
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 270
- Registration Number
- NCT06391775
- Locations
- 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇪🇸Hospital Universtari Val D´Hebron, Barcelona, Spain
🇪🇸Start Madrid Ciocc Hm Sanchinarro, Madrid, Spain
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
PRO1107 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 214
- Registration Number
- NCT06171789
- Locations
- 🇺🇸
START Mountain Cancer Center, Salt Lake City, Utah, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genmab
- Target Recruit Count
- 42
- Registration Number
- NCT06057038
- Locations
- 🇯🇵
National Cancer Center East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Genmab
- Registration Number
- NCT06046274
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain